Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Panorama City, California • Farmington, Connecticut • Chicago, Illinois + 5 more
Conditions
Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Ischemia, Blood Brain Barrier Defect
Interventions
Minocyclin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
P03277, Gadobenate dimeglumine, MRI
Drug · Device
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
Conditions
Blood Brain Barrier Defect
Interventions
Regadenoson, Temozolomide, Microdialysis catheter
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey